Drugs / Pegylated interferon alpha-2a (PegIFN)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01724086 Background | Oct 2012 → Sep 2014 | chronic hepatitis C virus infection | Janssen R&D Ireland | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated interferon alpha-2a (PegIFN) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01724086 ↗ |
| Route | Subcutaneous | “route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection” NCT01724086 ↗ |